XML 72 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
License Agreements - Merus (Details)
$ / shares in Units, $ in Thousands, € in Millions, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 23, 2017
USD ($)
$ / shares
Feb. 28, 2017
USD ($)
Jan. 31, 2017
USD ($)
item
Dec. 31, 2016
USD ($)
$ / shares
shares
Sep. 30, 2018
EUR (€)
Sep. 30, 2017
EUR (€)
Sep. 30, 2018
EUR (€)
Sep. 30, 2017
EUR (€)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
$ / shares
Dec. 31, 2017
EUR (€)
Dec. 31, 2017
USD ($)
License agreements                          
Long term investment                 $ 99,199       $ 134,356
Research and development expense                 1,197,957 $ 1,326,134 $ 581,861    
Unrealized gain (loss) on long term investments                 (44,093) (24,275) (3,261)    
Current assets                 1,832,254       1,504,854
Current liabilities                 425,277       375,396
Merus                          
License agreements                          
Number of independent programs | item     11                    
Upfront payment under license agreement   $ 120,000                      
Research and development expense                 10,300 6,500      
Merus | Accrued and other liabilities                          
License agreements                          
Accrued and other liabilities                 2,900       2,100
Merus | U.S.                          
License agreements                          
Profit sharing (as a percent)     50.00%                    
Percentage of profit (losses)     50.00%                    
Merus | Minimum                          
License agreements                          
Royalty payments on future global net sales (as a percent)     6.00%                    
Merus | Minimum | U.S.                          
License agreements                          
Royalty payments on future global net sales (as a percent)     6.00%                    
Merus | Minimum | Non-U.S.                          
License agreements                          
Royalty payments on future global net sales (as a percent)     6.00%                    
Merus | Maximum                          
License agreements                          
Royalty payments on future global net sales (as a percent)     10.00%                    
Percentage of additional royalties     4.00%                    
Percentage of reverse royalty     4.00%                    
Merus | Maximum | U.S.                          
License agreements                          
Royalty payments on future global net sales (as a percent)     10.00%                    
Merus | Maximum | Non-U.S.                          
License agreements                          
Royalty payments on future global net sales (as a percent)     10.00%                    
Merus | Maximum | Development and Regulatory Milestones                          
License agreements                          
Additional milestone payments under the license agreement     $ 100,000                    
Merus | Maximum | Commercialization Milestones                          
License agreements                          
Additional milestone payments under the license agreement     $ 250,000                    
Merus                          
License agreements                          
Number of programs under the resulting products are co-funded for development | item     2                    
Associated future global development costs , if elected to co-develop (as a percent)     35.00%                    
Total revenues | €         € 6.5 € 5.7 € 23.0 € 15.8          
Net income (loss) | €         (10.7) € (13.4) (23.7) € (52.7)          
Current assets | €         202.6   202.6         € 188.1  
Noncurrent assets | €         22.1   22.1         8.7  
Current liabilities | €         38.2   38.2         27.7  
Noncurrent liabilities | €         € 101.5   € 101.5         € 112.6  
Merus | Stock purchase agreement                          
License agreements                          
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares       3.2                  
Purchase price of common stock       $ 80,000             $ 80,000    
Per share price | $ / shares $ 24.50     $ 25.00             $ 25.00    
Lock-up period 18 months                        
Standstill period 3 years                        
Percentage of total shares allowed to sell during any 12-month period (as a percent) 33.00%                        
Percentage of total shares allowed to sell during any three-month period (as a percent) 10.00%                        
Discount for lack of marketability $ 5,600                        
Fair value of shares on the issuance date 72,800                        
Total consideration paid $ 80,000                        
Long term investment                         72,800
Research and development expense                   7,200      
Fair market value of our long term investments                 $ 44,800       $ 62,100
Ownership percentage (as a percent)                 14.00%        
Unrealized gain (loss) on long term investments                 $ (17,300) $ (10,700)